AEGIS-II: Negative Primary Endpoint but Infusions Might Benefit Subgroups of Patients
Infusions with human apolipoprotein A-1 failed to significantly reduce major adverse cardiovascular events in patients with myocardial infarction.
Read MoreInfusions with human apolipoprotein A-1 failed to significantly reduce major adverse cardiovascular events in patients with myocardial infarction.
Read MoreCombining a protein supplement with exercise improved strength, mobility, and balance after transcatheter aortic valve replacement.
Read MoreLerodalcibep reduced low-density lipoprotein-cholesterol (LDL-C) of 50–60% at week 52 of the phase 3 LIBerate-HR trial.
Read MoreDEDICATE trial shows transcatheter aortic valve implantation in patients with low-to-intermediate risk is not inferior to surgical aortic valve replacement.
Read MoreA single subcutaneous dose of zilebesiran was associated with a reduction in mean ambulatory and office systolic blood pressure.
Read More